INTRODUCTION
Autoimmune diseases vary significantly in their clinical presentations, but share the same pathophysiological mechanism resulting from a loss of self-tolerance. Despite significant advances in our understanding and management of autoimmune diseases, factors leading to this loss of self-tolerance are still poorly understood.
Studies in twins with autoimmune diseases show a much higher concordance rate in identical twins compared with nonidentical twins, indicative of a clear genetic component. However, the concordance rate is not 100% and the majority of identical twins with autoimmune diseases have a nonaffected twin [1] . In a recent review [2] monozygotic twin concordance rate was reported to be as low as 4.2 for systemic sclerosis. This suggests a second environmental factor triggering immune dysregulation in these genetically susceptible hosts leading to autoimmune diseases. Among the various possible environmental triggers, studies looking at the role of various infectious agents have been most promising [3 & ]. Microbial organisms are considered to be likely triggers of autoimmunity because of their ubiquitous presence in the environment and their interaction with the immune system. There are several proposed mechanisms by which microbial organisms can lead to loss of self-tolerance; such as molecular-mimicry, when shared amino acid sequences between microbial antigens and host proteins leads to a more generalized triggering of immune response against both the host proteins and microbial antigens [4] . Other proposed mechanisms leading to triggering of autoimmunity include polyclonal activation, epitope spread, bystander activation and superantigens [5] . Of the various bacteria and viruses proposed as agents triggering autoimmunity, Helicobacter pylori (H. pylori) is one of the most widely studied. This is because of attributes unique to H. pylori such as prolonged survival in host environment, worldwide prevalence, and its complex interactions with the host immune system. In this review, we will look at the interactions between H. pylori and the immune system in general and the role of H. pylori in individual autoimmune diseases.
INTERPLAY OF HELICOBACTER PYLORI AND THE IMMUNE SYSTEM
H. pylori is a curved gram-negative bacillus first identified from gastric mucosa by Marshall and Warren [6] . Most commonly H. pylori colonize the gastric mucosa in early childhood and can persist throughout life, if no antibiotic therapy is given [7] . Its worldwide prevalence is variable, with highest prevalence in areas with overcrowding and poor sanitation [8] . Presence of H. pylori in gastric mucosa has been associated with various gastrointestinal ailments, including peptic ulcers, noncardia gastric adenocarcinoma and gastric mucosa associated lymphoid tissue (MALT) lymphoma [7] .
Phylogeographic studies support the presence of helicobacter in our early east African ancestors more than 58 000 years ago [9] . H. pylori have managed to persist in their only confirmed hosts (humans) since then, living in the normally inhospitable acidic environment of the stomach. H. pylori have acquired several unique attributes helping them escape clearance through the normal immune mechanisms. This prolonged coexistence of H. pylori in humans raises the possibility of a rather symbiotic relationship in which its persistence may at least in part be beneficial to humans. Inverse association between the presence of H. pylori and gastroesophageal reflux disease, asthma and allergic disorders have been reported [7] . Epidemiological data suggest an increase in asthma and autoimmune diseases in populations wherein H. pylori infection is aggressively treated and being eradicated.
HELICOBACTER PYLORI AND THE INNATE IMMUNE SYSTEM
The innate immune system provides the first line of defense against invading microorganisms. This defense mechanism is based on recognition of microbial pathogen-associated molecular patterns (PAMP) through various pattern recognition receptors (PRR) present on the cells of the innate immune system. H. pylori recognition by PRR such as toll-like receptors (TLR) leads to a net anti-inflammatory effect. For example, as compared with lipopolysaccharide (LPS) from Escherichia coli, H. pylori LPS is found to be significantly less potent in promoting a proinflammatory response mediated via TLR 4 signaling [10] . Similarly, H. pylori flagellin evades recognition by TLR 5 [11] .
HELICOBACTER PYLORI AND THE ACQUIRED IMMUNE SYSTEM
H. pylori evade activation of the acquired immune system through their bacterial antigens. H. pylori vacuolating cytotoxin (VacA) blocks proliferation of CD4 þ helper T-lymphocytes, primarily by interfering with the T-cell receptor/interleukin (IL) 2 signaling pathway [12] . In experiments, when bone marrow derived dendritic cells were exposed to H. pylori, they failed to produce pro-inflammatory cytokines. In addition, H. pylori leads to a preferential priming of naïve T-cells into the anti-inflammatory regulatory T-cell (T-regs) [13 & ]. High antibody titers against H. pylori are usually present in infected individuals. But unlike other antimicrobial antibodies, anti-H. pylori antibodies [especially immunoglobulin (Ig)A antibodies] promote the presence of bacteria [14] . Studies in mouse models showed that B-lymphocyte activation by helicobacter species leads to an increase in the number of IL-10 (an anti-inflammatory cytokine) producing T-regs [15 & ].
HELICOBACTER PYLORI AND THE AUTOIMMUNE DISEASES-INDUCER OR PROTECTOR?
Evidence presented above indicates an overall downregulation of the host immune response in H. pylori infected individuals. However, the persistent presence of H. pylori in gastric mucosa results in chronic immune system activation with ongoing
KEY POINTS
Chronic infection with H. pylori has significant interactions with the immune system resulting in its downregulation.
Role of H. pylori in pathogenesis of autoimmune diseases remains controversial with some evidence even suggesting a protective role.
There are data suggesting positive association of H. pylori with immune thrombocytopenic purpura.
cytokine signaling, infiltration of gastric mucosa by neutrophils, macrophages, lymphocytes, as well as production of antibodies and effector T-cells [16] .
There are several proposed mechanisms by which H. pylori may cause loss of self-tolerance. These include molecular mimicry, polyclonal activation, epitope spread, bystander activation and super antigen phenomena. One example of molecular mimicry with the H. pylori antigens leading to an autoimmune disease is in the case of autoimmune chronic gastritis (AIG) in which, the recognized autoantigen is H þ , K þ -adenosine triphosphatase (H þ , K þ -ATPase). The activated CD4 þ T-lymphocytes in AIG were shown to cross react with H þ , K þ -ATPase and H. pylori antigens [17] . Similarly in studies on mice, B lymphocytes stimulated by H. pylori's urease antigen revealed production of several autoantibodies such as: IgM-type rheumatoid factor (RF IgM), anti-single-stranded DNA antibody, and anti-phosphatidylcholine (anti-PC) antibody [18 & ]. Conversely, there are some recent data suggestive of a protective effect of H. pylori against autoimmune and allergic diseases. A recent metaanalysis suggested a protective role of H. pylori in inflammatory bowel disease [19] . An inverse relationship between H. pylori infection and allergic conditions is also reported. Rate of asthma was found to be lower in children who were H. pylori positive when compared with those who were H. pylori negative [20 & ]. In a Japanese cohort an inverse association of H. pylori seropositivity and multiple sclerosis (MS) was reported [21] . Based on a review of literature recently, we concluded that in most autoimmune diseases the role of H. pylori remains inconclusive [22 && ].
Helicobacter pylori and immune thrombocytopenic purpura
Immune thrombocytopenic purpura (ITP) is an autoimmune disease resulting from antibodies against platelet glycoproteins. Several microbial agents causing chronic infections such as HIV, Hepatitis C virus and H. pylori have been shown to be associated with ITP.
In their recent review, Stasi et al. [23] reported worldwide prevalence of H. pylori in ITP patients from 25 studies. The result from these studies revealed an overall prevalence of 62.3%. However, when matched with age and geographic area prevalence rates of H. pylori infection in most of these studies were similar to the healthy population.
Several studies have attempted to explain the underlying pathogenic mechanism of H. pylori induced ITP. Most prevailing hypotheses suggest molecular mimicry between one of the H. pylori antigens and platelet glycoproteins causing production of cross-reacting autoantibodies [24] . A detailed discussion of H. pylori induced pathogenesis of ITP is beyond the scope of this review.
Eradication of H. pylori in patients with ITP leads to sustained increase in their platelet counts. A little over 50% of patients are expected to show an improvement in their platelet counts after eradication of H. pylori [25] . This response rate correlates with the prevalence of H. pylori in the population being treated, with higher response rates reported from Japan and much lower rates in studies from the United States.
Even though there is evidence of H. pylori infection in the development of ITP, its exact pathogenetic role is largely unknown.
Helicobacter pylori and rheumatoid arthritis
Looking for a microorganism causing rheumatoid arthritis (RA) dates back to the 19th century [26] . In a cohort of 187 samples from RA patients, 80.4% were found to be seropositive for H. pylori; however this was not significantly different from the control population, reflective of an overall increased prevalence [27] . In a study [28] of 1815 Japanese RA patients, 49.3% were reported to have H. pylori antibodies, which was lower compared with the healthy Japanese individuals. However, another study [29] from Japan looking at the prevalence of H. pylori infection in RA patients reported a much higher percentage (61.4%). Prevalence of H. pylori in the study [30] of a European population with RA was reported to be 48%, which is similar to healthy individuals in the Western countries. However, in the same study [30] , RA patients with H. pylori seropositivity showed a trend towards more severe disease and its eradication led to a significant improvement in RA related clinical outcomes. Hence, the role of H. pylori infection in causing RA is not clear; but its presence in patients with RA might result in a more severe phenotype.
Helicobacter pylori and systemic lupus erythematosus
A recent review looked at the role of various infectious agents including H. pylori in the development of SLE, concluding an overall negative association with H. pylori [31] . Studies done on mice revealed that H. pylori urease exposure can lead to production of anti-ss-DNA antibodies [32] . In a study [33] of 466 patients with SLE matched with 466 controls, SLE patients were less frequently seropositive (36.5%) for H. pylori as compared with healthy controls (42.9%) P ¼ 0.045. This negative association was even stronger for African-American female SLE patients as compared with controls (38.1 versus 60.2%; P ¼ 0.0009).
In another study [34] , patients with SLE were found to have lower titers of anti-H. pylori antibodies when compared with patients with other autoimmune diseases. These studies had several limitations but all of them are indicative of a negative association between SLE and H. pylori infection. This raises an interesting question: could H. pylori infected individuals be protected against development of SLE?
Helicobacter pylori and sjö gren's syndrome Some earlier studies suggested a possible association between H. pylori and Sjögren's syndrome [34] . One of the studies suggested a possible link between antibodies produced against heat shock protein (HSP 60) of H. pylori and development of Sjögren's syndrome [35] .
However subsequent studies failed to show any association between H. pylori seropositivity and presence of Sjögren's syndrome. In a study [36] of 164 Swedish patients with Sjögren's syndrome, H. pylori seroprevelance (45%) was similar to the controls. In addition there was no association found between H. pylori status and abnormal levels of autoantibodies or abnormal lip biopsy in these patients. In a separate cohort of 54 patients with Sjögren's syndrome, seroprevelance of H. pylori was 57% as opposed to 62% in the controls [37] . Authors also concluded that eradication of H. pylori was not associated with improvement of dyspeptic symptoms in patients with Sjögren's syndrome.
Helicobacter pylori and polymyositis and dermatomyositis
Limited data are available on any role of H. pylori and polymyositis (PM)/dermatomyositis (DM). Review of the available literature revealed no significant difference in frequency of H. pylori in patients with PM/DM compared with the controls [35, 38] .
Helicobacter pylori and systemic sclerosis
Several environmental factors including microbial organisms have long been debated as possible triggers for systemic sclerosis.
In a study [39] of 12 European scleroderma patients, five (42%) were found to be positive for H. pylori infection. In a much larger cohort of 124 Japanese patents with systemic sclerosis, seroprevelance of H. pylori was reported at 55.6%, much higher than the healthy controls [40] . Yet another study [41] found no difference in H. pylori infection rates between patients with systemic sclerosis and the controls. However, most of these patients in the study were infected with a more virulent (CagA) strain of H. pylori as compared with infected controls.
Several studies looked at association between specific manifestations of scleroderma and presence of H. pylori infection. In a Japanese study [42] , 64 patients with scleroderma underwent endoscopy to assess reflux esophagitis. Being infected with H. pylori was shown to be protective against development of reflux esophagitis in patients with scleroderma. There are conflicting reports of association between H. pylori and Raynaud's phenomena as reported in a recent review [43 & ].
Helicobacter pylori and vasculitis
In their search for a microbial agent causing Behcet's disease several investigators have looked at the seroprevelance of H. pylori in Behcet's disease patients.
Variable rates of H. pylori positivity are reported in patients with Behcet's disease from 85% (higher than controls) to 73.3% (lower than controls) [44, 45] . Several published case reports suggested an association of H. pylori infection with Henoch-Schönlein purpura, with resolution of symptoms coinciding with the eradication of H. pylori infection [46] .
In a study [47] looking at serological evidence of various infectious agents in patients with Granulomatosis with polyangitis (Wegner's Granulomatosis), H. pylori IgG antibodies were reported to be more common in patients as compared with controls.
Hence, there is some evidence of an association of H. pylori infection with various vasuilitides but further research is needed to infer any causality.
Helicobacter pylori and fibromyalgia
Etiology and pathogenesis of fibromyalgia (FMG) remain controversial. Studies focusing on association of several viral and bacterial microorganisms and FMG have been published, but literature regarding role of H. pylori is rather limited. A recent study [48 & ] explored association of FMG with H. pylori seropositivity in 65 patients and compared it with 41 age and gender-matched controls. Prevalence of IgG anti-H. pylori antibodies was significantly higher in FMG patients (30.8%) as compared with controls (17.1%). However, among these patients, there was no difference in clinical manifestations of FMG between H. pylori seropositive versus seronegative individuals. Another study [49] of 28 female FMG patients reported similar rates of H. pylori seropositivity in patients and controls.
CONCLUSION
H. pylori infection is very common and widespread. It has survived in its host (humans) for at least the last 58 000 years. H. pylori have extensive interactions with the immune system resulting in its downregulation. Their role as a causative agent of autoimmune diseases in genetically susceptible host has been extensively studied. Studies looking at the role of H. pylori in various autoimmune diseases found mixed results with some even suggesting a protective effect. However, mechanistic studies establishing causality are lacking. Further research looking at the possible role of H. pylori in autoimmune diseases is needed.
